News
Brief news reports on Tuberculosis
By
International Union Against Tuberculosis and Lung Disease
Published: March 8, 2024, 9:32 p.m.·
Tags:
Global TB response,
Public health
The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).
Read More →
By
Tara Haelle
Published: March 7, 2024, 9:40 p.m.·
Tags:
Treatment
DENVER, March 7, 2024 -- In patients with tuberculosis (TB), a novel fixed-dose combination of alpibectir-ethionamide had similar levels of bactericidal activity as isoniazid, with no serious adverse events and good tolerability, a phase II randomized controlled trial showed.
Read More →
By
World Health Organization
Published: March 6, 2024, 8:01 p.m.·
Tags:
Global TB response,
Advocacy
On World TB Day, WHO is calling for action on several fronts to ensure that the commitments made to end TB are achieved. WHO releases an advocacy and communications World TB Day campaign package.
Read More →
By
Gilead Sciences
Published: March 6, 2024, 4:37 p.m.·
Tags:
HIV coinfection,
Treatment
March 06, 2024: Gilead Sciences, Inc. announced new data from three studies evaluating the efficacy and safety profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) for a broad range of people with HIV, including those with HIV/hepatitis B (HBV) coinfection and HIV/tuberculosis (TB) coinfection. These data and other studies supporting the important role of Biktarvy in the HIV treatment landscape were presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).
Read More →
By
Sophia Abene
Published: March 6, 2024, 3:12 p.m.·
Tags:
HIV coinfection,
Prevention,
Treatment
Latent Tuberculosis Infection (LTBI) is associated with increased immune activation and a heightened risk of cardiovascular diseases. The ACTG A5279 trial, a phase 3 study presented at the Conference on Retroviruses and Opportunistic Infections (CROI), investigated the activation patterns of monocytes in individuals with HIV (PWH). This trial compared the efficacy of 4 weeks of daily rifapentine (RFP) and isoniazid (INH) against 9 months of daily INH for Tuberculosis Preventive Therapy (TPT). At baseline and week 48, PWH with LTBI, compared to those with negative TST/IGRA results, demonstrated changes in monocytes indicative of ongoing activation and tissue migration.
Read More →
By
Treatment Action Group
Published: March 5, 2024, 7:49 p.m.·
Tags:
Treatment
Treatment Action Group launches the 2023 Tuberculosis Treatment Pipeline Report.
Read More →
By
IMPAACT4TB
Published: March 5, 2024, 1:52 p.m.·
Tags:
HIV coinfection,
Prevention
For people starting HIV treatment, combining dolutegravir-containing antiretroviral therapy with 3HP TB preventive treatment is safe and works effectively in tandem.
Read More →
By
RESIST-TB
Published: March 4, 2024, 6:47 p.m.·
Tags:
Drug-resistant TB
RESIST-TB released its March 2024 newsletter with the latest updates and research publications on drug-resistant TB.
Read More →
By
Global Fund to Fight AIDS, Tuberculosis and Malaria
Published: March 4, 2024, 3:38 p.m.·
Tags:
TB programs
Since the expansion of the war in Ukraine in February 2022, more than 14 million people have been internally displaced or forced to flee to neighboring countries as refugees, often losing access to health care. HIV and TB prevention and diagnosis services have been disrupted, and many people with HIV and TB have been forced to interrupt their lifesaving treatment. The war has left hundreds of thousands of people without electricity or water supplies, and almost half of the population is in need of humanitarian assistance.
Read More →
By
Treatment Action Group
Published: Feb. 29, 2024, 8:30 p.m.·
Tags:
Prevention
Educational materials designed for community-based and civil society organizations to use to advocate for and teach people about TB preventive treatment.
Read More →
Page 3 of 878 · Total posts: 10
←First
2
3
4
Last→